ReviewEchinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives
Introduction
Candidaemia and invasive candidiasis (IC) are increasingly common, costly and life-threatening infections, particularly among the immunocompromised and critically ill [1], [2], [3]. Surveillance programmes in the USA report Candida spp. as the fourth leading isolate and the only fungal pathogen among the top 10 causative organisms for nosocomial bloodstream [4] and healthcare-associated infections [5]. Globally, Candida spp. ranked number three for causing infections in intensive care units (ICUs) [6]. More than 70% of invasive fungal infections in hospitalised patients were due to Candida spp., the majority presenting as candidaemia [7]. Population-based studies on the incidence of candidaemia (1991–2006) in Europe, Canada, the USA and Australia reported 1.7–24.0 cases per 100 000 head of population per year [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]. In the USA, the incidence of IC has increased to 29 cases per 100 000 head of population per year in 2003, translating to an annual national burden of about 63 000 infections [20]. Not only is the burden of candidaemia and IC substantial [21], [22], [23], [24], a shift in the proportion of cases occurring in specialised hospital wards and ICUs to the general hospital and community settings has also been noted for candidaemia [12], [25].
Crude and attributable mortalities of candidaemia and IC have been reported as 28–81% and 15–71%, respectively [19], [21], [23], [24], [26], [27], [28], [29], [30], [31]. These infections have resulted in prolonged hospital stays of 3–30 days [22], [23], [26], [27], [30], [32] and in additional costs of US$21, 590–68, 311 per patient [22], [23], [30], [32] or US$216–281 million per year [22]. Given the significant clinical and economic burden, identifying an optimal approach to treating candidaemia and IC is important. Accordingly, this review will provide a brief overview of the epidemiology and current treatment options for candidaemia and IC. It will focus primarily on clinical and pharmacoeconomic data as well as the considerations, challenges and gaps for future pharmacoeconomic research for the antifungal agents used in this setting, in particular the echinocandins.
There are at least 17 pathogenic Candida species and/or species complexes, but >90% of invasive infections are attributed to five species, namely Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis and Candida krusei [20], [33]. However,
species epidemiology of candidaemia varies in different parts of the world and the relative incidence of the various Candida spp. is changing over time [34]. Multicentre and laboratory-based surveillance programmes (1997–2006) reported that C. albicans was the predominant isolate (>60%) in North Europe and Switzerland and comprised 48–58% of the Candida spp. isolated in the remaining European countries and the USA; non-albicans spp. (58–60% of the Candida isolates) were more commonly found in Asia and South America [34]. Local hospital- or ICU-based epidemiological studies have also reported similar patterns, except in the USA (predominantly C. albicans) and southern Europe (non-albicans spp. predominated) [34]. In Australia, C. albicans accounts for 47.3–62.0% of invasive Candida isolates, followed by C. parapsilosis (7.8–19.9%), C. glabrata (13.0–17.9%), C. tropicalis (4.4–5.6%) and C. krusei (3.9–4.9%) [19], [35], [36]. Although C. albicans remains the most common species in candidaemia and IC isolates, lately there appears to be a shift towards non-albicans spp. [19], [36], as evidenced in recent surveillance studies worldwide [37], [38], [39], [40].
To optimise clinical outcomes for patients with candidaemia and IC, appropriate selection of antifungal agent and timing of antifungal treatment are critical [41]. Inappropriate selection or delays in antifungal therapy are linked to poorer prognosis, increased mortality and substantial costs [42], [43], [44], [45], [46], [47]. According to the clinical practice guidelines developed by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) [48], the Infectious Diseases Society of America (IDSA) [2], the Australian consensus working group [1] and the German-speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy [49], several classes of antifungal agents can be used for the treatment of IC. These include triazoles (i.e. fluconazole and voriconazole), echinocandins (i.e. caspofungin, micafungin and anidulafungin) and polyenes [i.e. liposomal amphotericin B (LAmB) and conventional amphotericin B (CAmB)]. The choice of antifungal agents is mainly influenced by the presence of co-morbid conditions (e.g. renal failure) and the clinical status of the patient, followed by a patient's previous exposure to antifungal agents and incidence of fluconazole-resistant non-albicans strains [50].
Section snippets
Clinical efficacy and safety of antifungal agents in candidaemia and invasive candidiasis
Earlier clinical studies have demonstrated comparable efficacy between fluconazole and CAmB for treating candidaemia in non-neutropenic patients, but more adverse events were observed in the CAmB arm [51], [52], [53]. Fluconazole is recommended due to its proven efficacy, low toxicity, relatively low cost, and availability for both parenteral and enteral administration [1]. Fungal susceptibility to fluconazole, however, has become a major concern. Although C. albicans generally remains
Challenges and gaps for future research
One of the major challenges associated with pharmacoeconomic evaluations in the candidaemia and IC setting is the lack of an appropriate, standardised, comprehensive outcome (effectiveness) measure that allows for meaningful comparison across studies, in addition to the inconsistencies in the study design, depth and quality of the methodologies employed. This is further complicated by the dearth of head-to-head RCTs in demonstrating clear superiority of one antifungal treatment option over the
Conclusion
The modest expansion in the antifungal armamentarium has provided more options for treating candidaemia and IC. Echinocandins are among the recommended first-line therapies for treatment of candidaemia and IC, given their clinical efficacy and safety. Nevertheless, they are expensive. Based on the current literature, treatment with echinocandins is cost effective or cost saving compared with polyenes or azoles, primarily due to the lower incidence of drug-related adverse events. Existing
References (101)
- et al.
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Lancet Infect Dis
(2003) - et al.
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections
Diagn Microbiol Infect Dis
(2007) - et al.
Excess mortality, length of stay and cost attributable to candidaemia
J Infect
(2009) - et al.
Candidaemia: incidence, risk factors, characteristics and outcomes in immunocompetent critically ill patients
Clin Microbiol Infect
(2009) - et al.
Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review
Int J Infect Dis
(2010) - et al.
Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999–2008
J Hosp Infect
(2010) - et al.
Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study
Int J Antimicrob Agents
(2007) - et al.
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
Clin Microbiol Infect
(2012) - et al.
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
Lancet
(2005) - et al.
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Lancet
(2007)
Treatment of invasive candidal infections: systematic review and meta-analysis
Mayo Clin Proc
Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis
Clin Ther
Transportability of comparative effectiveness and cost-effectiveness between countries
Value Health
Recommendations for the treatment of established fungal infections
Intern Med J
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
Clin Infect Dis
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study
Clin Infect Dis
NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007
Infect Control Hosp Epidemiol
International study of the prevalence and outcomes of infection in intensive care units
JAMA
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003
J Clin Microbiol
Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility
J Clin Microbiol
Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland
J Clin Microbiol
Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study
J Clin Microbiol
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program
J Clin Microbiol
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance
Clin Infect Dis
Invasive Candida species infections: a 5 year population-based assessment
J Antimicrob Chemother
One year prospective survey of Candida bloodstream infections in Scotland
J Med Microbiol
Secular trend in candidemia and the use of fluconazole in Finland, 2004–2007
BMC Infect Dis
Candidemia in Finland, 1995–1999
Emerg Infect Dis
Candidemia in Norway (1991 to 2003): results from a nationwide study
J Clin Microbiol
Active surveillance for candidemia, Australia
Emerg Infect Dis
Epidemiology of invasive candidiasis: a persistent public health problem
Clin Microbiol Rev
Excess mortality, hospital stay, and cost due to candidemia: a case–control study using data from population-based candidemia surveillance
Infect Control Hosp Epidemiol
The impact of candidemia on length of hospital stay, outcome, and overall cost of illness
Clin Infect Dis
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis
Clin Infect Dis
Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999
Clin Infect Dis
Attributable mortality of nosocomial candidemia, revisited
Clin Infect Dis
Hospital-acquired candidemia. The attributable mortality and excess length of stay
Arch Intern Med
Has the epidemiology of nosocomial candidemia changed?
Infect Control Hosp Epidemiol
Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients
Ann Surg
Cost associated with candidemia in a hospital setting
P & T
Candida infections: outcome and attributable ICU costs in critically ill patients
J Intensive Care Med
Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus
J Clin Microbiol
Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp
Crit Care Med
The epidemiology of candidaemia and mould infections in Australia
J Antimicrob Chemother
Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance registry
Clin Infect Dis
Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain
J Clin Microbiol
Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study
Med Mycol
Candidemia in the in-patient setting: treatment options and economics
Expert Opin Pharmacother
Time to initiation of fluconazole therapy impacts mortality in patients with candidaemia: a multi-institutional study
Clin Infect Dis
Hospital resource utilization and costs of inappropriate treatment of candidemia
Pharmacotherapy
Cited by (25)
Functional expression of an echinocandin B deacylase from Actinoplanes utahensis in Escherichia coli
2021, International Journal of Biological MacromoleculesCitation Excerpt :Since cell walls are present in fungal cells but absent in animal cells, the fungal cell wall perhaps represents the ideal target for treating fungal pathogens in humans [2,3]. As the first class of antifungals to target the fungal cell wall, echinocandins have become the first-line antifungal treatment of candidaemia and other forms of invasive candidiasis (IC) [4,5]. The three currently approved drugs, caspofungin, micafungin, and anidulafungin, were discovered through the synthetic modification of echinocandin natural products obtained from fermentation.
Proteomic analysis of fungal species in response to various antifungal agents for novel drug development
2020, New and Future Developments in Microbial Biotechnology and Bioengineering: Recent Advances in Application of Fungi and Fungal Metabolites: Biotechnological Interventions and Futuristic ApproachesDesign and studies of multiple mechanism of anti-Candida activity of a new potent Trp-rich peptide dendrimers
2015, European Journal of Medicinal ChemistryCitation Excerpt :Indeed, as showed previously [34,35], Trp has a crucial role in the membrane-directed antimicrobial activity of various linear peptides. Moreover, it was found that 14 is an efficient inhibitor of C. krusei intrinsically resistant to fluconazole [36]. Numerous examples of toxicity studies of polycationic compounds like PAMAM or PPI dendrimers and AMP's evidence that high activity, often associated with high charge is also often accompanied by enhanced toxicity [37,38].
One Health Approach to Addressing Fungal Infection Disparities
2024, Current Fungal Infection ReportsInvasive candidiasis: current clinical challenges and unmet needs in adult populations
2023, Journal of Antimicrobial ChemotherapyHealth-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis
2023, JAC-Antimicrobial Resistance